Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEDICATE-LPS experimental human endotoxemia study
2023-506556-24-00Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dexamethasone, tocilizumab and anakinra in Systemic Inflammatory Response Syndrome (SIRS) (4 arms), sponsored by Radboud University Medical Center. Primary endpoint: Plasma TNF concentration after second LPS challenge. Started Oct 2024; status: completed.
02
Drugs
dexamethasonetocilizumabanakinra
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on 2023-506556-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506556-24-00.